Clinical trials for lung cancer
130 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 2
Lung cancer
#NCT02611024
SCLC (Small Cell Lung Cancer)
Locally Advanced
Metastatic
Chemotherapy
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif)
PharmaMar
Phase 2
Lung cancer
#NCT04585750
Locally Advanced
Metastatic
KRAS G12C
KRAS non G12C
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre Léon Bérard (Lyon), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux) (and 2 more...)
PMV Pharmaceuticals, Inc
Phase 2
Lung cancer
#NCT03175224
Locally Advanced
Metastatic
MET
EGFR
BRAF
ALK
RET
ROS-1
NTRK-1/2/3
KRAS G12C
KRAS non G12C
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Universitaire de Lille (Lille), Centre Léon Bérard (Lyon), CHU de Rennes - Hôpital Pontchaillou (Rennes), Gustave Roussy (Villejuif), Hôpital de la Timone AP-HM (Marseille) (and 2 more...)
Apollomics
Phase 2
Lung cancer
#NCT03175224
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
MET
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
EGFR
BRAF
ALK
RET
ROS-1
NTRK-1/2/3
KRAS G12C
KRAS non G12C
Targeted therapy
Centre Hospitalier Universitaire de Lille (Lille), Centre Léon Bérard (Lyon), CHU de Rennes - Hôpital Pontchaillou (Rennes), Gustave Roussy (Villejuif), Hôpital de la Timone AP-HM (Marseille) (and 2 more...)
Apollomics
Phase 2
Lung cancer
#NCT05676931
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
Hôpital Foch (Suresnes), Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon)
Arcus Biosciences
Phase 2
Lung cancer
#NCT05635708
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
EGFR
BRAF
ALK
RET
ROS-1
Immunotherapy
Institut Curie - Paris (Paris), Centre Hospitalier Universitaire Laennec (Saint-Herblain)
BeiGene
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
#NCT05751798
MSI/dMMR
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Systemic Treatment-Naive
Immunotherapy
Systemic Treatment-Naive
Immunotherapy
Centre Léon Bérard (Lyon)
OSE Immunotherapeutics
Phase 2
Lung cancer
#NCT05384626
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
ALK
Immunotherapy
Chemotherapy
Targeted therapy
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Gustave Roussy (Villejuif), Centre Léon Bérard (Lyon), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Nuvalent Inc.
Phase 2
Lung cancer
#NCT05142696
SCLC (Small Cell Lung Cancer)
Locally Advanced
Metastatic
Systemic Treatment-Naive
Immunotherapy
Hôpital de la Timone AP-HM (Marseille), Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier)
Novartis
Phase 2
Lung cancer
#NCT05781308
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Chemotherapy
Immunotherapy
ALK
EGFR
NTRK-1/2/3
RET
ROS-1
Systemic Treatment-Naive
Targeted therapy
Polyclinique Bordeaux Nord Aquitaine (Bordeaux), Hôpital Ambroise-Paré AP-HP (Boulogne-Billancourt), CHU Caen Normandie (Caen), Ghrmsa - Hôpital Emile Muller (Mulhouse), CHU - Haut-lévêque - Bordeaux (Pessac)
Intergroupe Francophone de Cancérologie Thoracique